---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002706"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:47.103075+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics outlines 2026 milestones; zelenectide pevedotin dose selection & approval pathway update in Q1

## Summary
- Dose selection from Phase 2/3 Duravelo-2 trial and approval update for zelenectide pevedotin in mUC expected in Q1 2026
- Additional EphA2 human imaging data for radiopharmaceuticals pipeline planned for first half of 2026
- Initial data from Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer expected in second half of 2026
- Financial runway expected into 2028 to support execution of clinical and strategic priorities

## SEC filing metadata
- accession: 0001104659-26-002706
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465926002706/0001104659-26-002706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465926002706/tm262874d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002706
- JSON: https://secwatch.observer/filing/0001104659-26-002706.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.